Irritable bowel syndrome and functional GI motility — the only peptide-pharmacology territory with two FDA-approved class members

Why this dossier exists

Functional gastrointestinal disorders — the umbrella the Rome Foundation now formalises as disorders of gut-brain interaction (DGBI) — are the territory where peptide pharmacology has produced two FDA-approved class members on placebo-controlled randomized-trial evidence at multi-hundred-patient scale. Linaclotide (Linzess, Ironwood/Allergan/AbbVie, approved August 2012) and plecanatide (Trulance, Synergy/Salix, approved January 2017) are both small cyclic peptides that activate the intestinal guanylate cyclase-C (GC-C) receptor on the apical brush border of enterocytes, drive cGMP-mediated chloride and bicarbonate secretion through the CFTR channel, accelerate intestinal transit, and produce a parallel visceral-analgesic effect via extracellular cGMP acting on submucosal nociceptors. Both molecules are FDA-approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The development arc that produced them is the single cleanest worked example in the corpus of how a peptide indication targeting a luminal GI epithelial receptor can survive rigorous development and a Phase III readout.

The disease background sets the framing. Irritable bowel syndrome is the most common functional bowel disorder, with pooled global prevalence estimates of 9.2% under Rome III criteria and 3.8% under the stricter Rome IV criteria (Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC, Lancet Gastroenterol Hepatol 2020, 5:908-917) — the difference between the two figures is the result of the tighter symptom-frequency threshold Rome IV imposes rather than a real shift in underlying disease frequency. The Sperber AD, Bangdiwala SI, Drossman DA et al., Gastroenterology 2021, 160:99-114 Rome Foundation Global Study across 33 countries reported that more than one in four adults meet Rome IV criteria for at least one FGID. Diagnostic phenotype is partitioned into IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), IBS-M (mixed), and IBS-U (unclassified) by stool form, with the contemporary management framework anchored by the Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B, Am J Gastroenterol 2021, 116:17-44 ACG Clinical Guideline. The adjacent CIC indication (chronic idiopathic constipation, the non-IBS constipation phenotype where abdominal pain is not the dominant symptom) is the second labelled population for both GC-C agonists.

The peptide conversation around IBS and functional GI sorts into three distinct frames. The directly-peptide-targeting class — linaclotide, plecanatide, and the engineered uroguanylin / guanylin family they derive from — is the only peptide pharmacology in this dossier with FDA approval inside an IBS indication. The peptide-axis-modulator class — GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) — modulates upper GI motility as a central pharmacology rather than treating IBS, producing the most consequential functional-GI side effect signal in modern medicine. The peripheral peptide-pharmacology candidates — GLP-2 / teduglutide on mucosal-trophic mechanism, larazotide on tight-junction modulation, VIP on enteric motility — sit on the IBS conversation's periphery without controlled-trial evidence for the indication. Small-molecule comparators (tenapanor, lubiprostone, eluxadoline, rifaximin, prucalopride) anchor the standard-of-care frame any peptide discussion sits inside.